Sign In

Login

Password

Forgot Password ? Sign Up

细胞因子诱导的杀伤细胞 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "细胞因子诱导的杀伤细胞" in Chinese language version.

refsWebsite
Global rank Chinese rank
19doi.org
2nd place
23rd place
16nih.gov
4th place
5th place
6web.archive.org
1st place
1st place
2archive.org
6th place
4th place
1scmp.com
362nd place
236th place
1archive.today
14th place
18th place
1sohu.com
343rd place
13th place
1nature.com
234th place
227th place
1chinanews.com
1,432nd place
50th place
1gjzlx.cn
low place
low place
1stdaily.com
low place
2,951st place

archive.org

archive.today

chinanews.com

doi.org

dx.doi.org

gjzlx.cn

nature.com

nih.gov

ncbi.nlm.nih.gov

  • Schmidt-Wolf, IG; Negrin, RS; Kiem, HP; Blume, KG; Weissman, IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.. The Journal of Experimental Medicine. 1 July 1991, 174 (1): 139–49. PMID 1711560. doi:10.1084/jem.174.1.139. 
  • Schmidt-Wolf, IG; Lefterova, P; Mehta, BA; Fernandez, LP; Huhn, D; Blume, KG; Weissman, IL; Negrin, RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.. Experimental hematology. December 1993, 21 (13): 1673–9. PMID 7694868. 
  • Lu, PH; Negrin, RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.. Journal of immunology (Baltimore, Md. : 1950). 15 August 1994, 153 (4): 1687–96. PMID 7519209. 
  • Pievani, A; Borleri, G; Pende, D; Moretta, L; Rambaldi, A; Golay, J; Introna, M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.. Blood. 22 September 2011, 118 (12): 3301–10. PMID 21821703. doi:10.1182/blood-2011-02-336321. 
  • Godfrey, DI; MacDonald, HR; Kronenberg, M; Smyth, MJ; Van Kaer, L. NKT cells: what's in a name?. Nature reviews. Immunology. March 2004, 4 (3): 231–7. PMID 15039760. doi:10.1038/nri1309. 
  • Schmidt-Wolf, IG; Finke, S; Trojaneck, B; Denkena, A; Lefterova, P; Schwella, N; Heuft, HG; Prange, G; Korte, M; Takeya, M; Dorbic, T; Neubauer, A; Wittig, B; Huhn, D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.. British Journal of Cancer. November 1999, 81 (6): 1009–16. PMID 10576658. doi:10.1038/sj.bjc.6690800. 
  • Introna, M; Pievani, A; Borleri, G; Capelli, C; Algarotti, A; Micò, C; Grassi, A; Oldani, E; Golay, J; Rambaldi, A. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. November 2010, 16 (11): 1603–7. PMID 20685246. doi:10.1016/j.bbmt.2010.05.015. 
  • Li, H; Yu, JP; Cao, S; Wei, F; Zhang, P; An, XM; Huang, ZT; Ren, XB. CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients.. Journal of clinical immunology. May 2007, 27 (3): 317–26. PMID 17468835. doi:10.1007/s10875-007-9076-0. 
  • Schmeel, LC; Schmeel, FC; Coch, C; Schmidt-Wolf, IG. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).. Journal of cancer research and clinical oncology. 8 November 2014, 141: 839–49. PMID 25381063. doi:10.1007/s00432-014-1864-3. 
  • Hontscha, C; Borck, Y; Zhou, H; Messmer, D; Schmidt-Wolf, IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).. Journal of cancer research and clinical oncology. February 2011, 137 (2): 305–10. PMID 20407789. doi:10.1007/s00432-010-0887-7. 
  • Märten, A; Ziske, C; Schöttker, B; Renoth, S; Weineck, S; Buttgereit, P; Schakowski, F; von Rücker, A; Sauerbruch, T; Schmidt-Wolf, IG. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2000, 24 (6): 502–10. PMID 11759073. doi:10.1097/00002371-200111000-00007. 
  • Schmidt, J; Eisold, S; Büchler, MW; Märten, A. Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma.. Cancer immunology, immunotherapy : CII. November 2004, 53 (11): 1018–26. PMID 15185013. doi:10.1007/s00262-004-0554-4. 
  • Hombach, AA; Rappl, G; Abken, H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".. Molecular therapy : the journal of the American Society of Gene Therapy. December 2013, 21 (12): 2268–77. PMID 23985696. doi:10.1038/mt.2013.192. 
  • Chan, JK; Hamilton, CA; Cheung, MK; Karimi, M; Baker, J; Gall, JM; Schulz, S; Thorne, SH; Teng, NN; Contag, CH; Lum, LG; Negrin, RS. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15 March 2006, 12 (6): 1859–67. PMID 16551871. doi:10.1158/1078-0432.ccr-05-2019. 
  • Tita-Nwa, F; Moldenhauer, G; Herbst, M; Kleist, C; Ho, AD; Kornacker, M. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.. Cancer immunology, immunotherapy : CII. December 2007, 56 (12): 1911–20. PMID 17487487. doi:10.1007/s00262-007-0333-0. 
  • Zhong R; Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer.. Cancer Immunol Immunother. 2011-10, 60 (10): 1497–1502 [2016-05-02]. doi:10.1007/s00262-011-1060-0. （原始内容存档于2016-09-20） （英语）. 

scmp.com

sohu.com

business.sohu.com

stdaily.com

digitalpaper.stdaily.com

web.archive.org